Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OIGIT 5-01: Capecitabine in Locally Advanced Rectal Cancer
NCT01489332Phase 2Unknown
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Oct 2011
- Primary completion
- Apr 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in rectal cancer, sponsored by Institute of Oncology Ljubljana. Status: unknown.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01489332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01489332.